The U.S. government has ordered another 600,000 doses of sotrovimab, developed by GlaxoSmithKline and Vir Biotechnology. The drug is designed to treat COVID-19 at an early stage. The companies will deliver additional doses during Q1 2022. In total, GSK and Vir have signed agreements to supply approximately 1.7 million doses of sotrovimab worldwide.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept